Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05723562 | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer(AZUR-1) | active not recruiting | Phase 2 | 154 | GlaxoSmithKlineINDUSTRY | 10 | May 26, 2026 | clinicaltrials |
| NCT06274879 | Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer(Ablatio) | recruiting | Phase 2 | 36 | Insel Gruppe AG, University Hospital BernOTHER | 1 |
| May 26, 2026 |
| clinicaltrials |
| NCT06427239 | Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 130 | Fudan UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07176182 | Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression | recruiting | Phase 2 | 236 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03548961 | Organ Preservation in Early Rectal Cancer Patients | active not recruiting | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04196465 | Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers(NeoChance) | active not recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04494009 | PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy(RHAPSODY) | active not recruiting | Phase 2 | 110 | Asan Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04503694 | Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer(REGINA) | active not recruiting | Phase 2 | 72 | Jules Bordet InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05571293 | Combination Immunotherapy in Colorectal Cancer(NEST-1) | active not recruiting | Phase 2 | 26 | Weill Medical College of Cornell UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06067438 | Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | recruiting | Phase 2 | 90 | OHSU Knight Cancer InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06567782 | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer(AZUR-4) | recruiting | Phase 2 | 120 | GlaxoSmithKlineINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | recruiting | Phase 1 / Phase 2 | 307 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06890624 | mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer(OPTICAL-3) | not yet recruiting | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT06903858 | Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer(PICC-3) | recruiting | Phase 2 | 105 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07263594 | A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors | recruiting | Phase 1 / Phase 2 | 127 | DualityBio Inc.INDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07493668 | Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy(FLEX-HCC) | recruiting | Phase 2 | 80 | CHA UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07595835 | CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer(PANCOSIL) | recruiting | Phase 1 / Phase 2 | 20 | M.R. MeijerinkOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07603349 | Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 2 / Phase 3 | 405 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07604909 | A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06959550 | Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer | recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07038629 | Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC | recruiting | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07205731 | Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma(SAFE ESO) | recruiting | Phase 2 | 95 | University Hospital, Clermont-FerrandOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07587034 | HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer | not yet recruiting | Phase 1 / Phase 2 | 315 | Shanghai Zhongshan HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07587619 | Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion | active not recruiting | Phase 1 / Phase 2 | 52 | University of Southern CaliforniaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07595523 | Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency | not yet recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations | not yet recruiting | Phase 2 / Phase 3 | 164 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07599995 | Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies(GENE) | not yet recruiting | Phase 2 | 34 | Sir Run Run Shaw HospitalOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT07600268 | Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer | recruiting | Phase 2 | 24 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection | recruiting | Phase 2 | 320 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT06904378 | ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07173387 | Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer(RAD-NALIRIFOX) | active not recruiting | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab(GOBLET) | active not recruiting | Phase 1 / Phase 2 | 122 | Oncolytics BiotechINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07359456 | Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases(COLIBRI-GI) | not yet recruiting | Phase 2 | 130 | UNICANCEROTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07594925 | Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07595172 | NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 55 | West China HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07595770 | Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma(ANCRE) | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03386500 | Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT06769113 | A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy | recruiting | Phase 2 | 102 | Shanghai Henlius BiotechINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT06824064 | Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer(VISTA-1) | recruiting | Phase 2 | 150 | Riboscience, LLC.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT07581626 | Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07591597 | A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer(IGNITE-CRC) | not yet recruiting | Phase 1 / Phase 2 | 68 | National Cancer Center Hospital EastOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | active not recruiting | Phase 2 | 32 | Academic and Community Cancer Research UnitedOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06251973 | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
Data updated 24 days agoSource updated May 26, 2026source: clinicaltrials